Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies
Background/Objectives: DESTINY-PanTumor02 demonstrated clinically meaningful activity of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gynecologic cancers, contributing to regulatory approval for unresectable or metastatic HER2 immunohistochemistry (IHC) 3+ solid tumors. Evidence in gynecologic malignancies with low HER2 expression remains limited. We evaluated T-DXd in a predominantly HER2-low, heavily pretreated population. Methods: This retrospective, single-center cohort study included 11 patients with recurrent gynecologic malignancies who initiated therapy with T-DXd at the Medical University of Innsbruck between January 2024 and February 2026 following progression on standard-of-care treatment. The cohort comprised patients with ovarian (n = 6), endometrial (n = 2), and cervical cancer (n = 3). Treatment response, survival outcomes, and adverse events were assessed. Results: Among 11 heavily pretreated patients, seven (64%) had tumors with HER2 IHC 1+, three (27%) had HER2 IHC 2+/ISH negative, and one (9%) had HER2 IHC 3+ expression. The overall response rate was 67% (6/9; 95% CI 29.9–92.5) and disease control rate was 78% (7/9; 95% CI 40.0–97.2). Kaplan–Meier median duration of response was 4.6 months (95% CI, 1.9–7.3), with two responses ongoing at 8.7 and 20.1 months. Median progression-free and overall survival were 7.0 months (95% CI, 1.6–12.4) and 12.0 months (95% CI, 8.3–15.7), respectively. Treatment-associated adverse events occurred in 73% of patients, including interstitial lung disease in two patients. Conclusions: T-DXd showed antitumor activity in this predominantly HER2-low real-world cohort. These findings support further clinical investigation of T-DXd in patients with low HER2 expressing gynecological malignancies.
Authors
- Katharina Leitner (ORCID: https://orcid.org/0000-0002-9572-9114)
- Christian Marth (ORCID: https://orcid.org/0000-0002-8965-9981)
- Irina Tsibulak (ORCID: https://orcid.org/0000-0001-6795-3015)
- Verena E. Wieser (ORCID: https://orcid.org/0000-0001-6121-2515)
- Christoph Ebner (ORCID: https://orcid.org/0000-0002-2033-6228)
- Susanne Sprung
- İbrahim Alkatout (ORCID: https://orcid.org/0000-0002-7194-6034)
- Barin Feroz (ORCID: https://orcid.org/0009-0001-5064-1397)
- Katharina Steger (ORCID: https://orcid.org/0009-0007-1749-0017)
Institutions
- Innsbruck Medical University (AT)
- Tirol Kliniken (AT)
Publication Details
- Journal
- Cancers
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3390/cancers18223673
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00